Supplying a pharmacy for NASA exploration spaceflight: challenges and current understanding

Rebecca Blue, Tina M. Bayuse, Vernie R. Daniels, Virginia E. Wotring, Rahul Suresh, Robert A. Mulcahy, Erik L. Antonsen

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

In order to maintain crew health and performance during long-duration spaceflight outside of low-Earth orbit, NASA and its international partners must be capable of providing a safe and effective pharmacy. Given few directed studies of pharmaceuticals in the space environment, it is difficult to characterize pharmaceutical effectiveness or stability during spaceflight; this in turn makes it challenging to select an appropriate formulary for exploration. Here, we present the current state of literature regarding pharmaceutical stability, metabolism, and effectiveness during spaceflight. In particular, we have attempted to highlight the gaps in current knowledge and the difficulties in translating terrestrial-based drug studies to a meaningful interpretation of drug stability, safety, and effectiveness in space. We hope to identify high-yield opportunities for future research that might better define and mitigate pharmaceutical risk for exploration missions.

Original languageEnglish (US)
Article number14
Journalnpj Microgravity
Volume5
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

United States National Aeronautics and Space Administration
space flight
Space Flight
supplying
Drug products
NASA
drug
drugs
Pharmaceutical Preparations
translating
crews
aerospace environments
low Earth orbits
metabolism
health
safety
Drug Stability
Formularies
Metabolism
Orbit

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Materials Science (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology (miscellaneous)
  • Agricultural and Biological Sciences (miscellaneous)
  • Physics and Astronomy (miscellaneous)
  • Space and Planetary Science

Cite this

Blue, R., Bayuse, T. M., Daniels, V. R., Wotring, V. E., Suresh, R., Mulcahy, R. A., & Antonsen, E. L. (2019). Supplying a pharmacy for NASA exploration spaceflight: challenges and current understanding. npj Microgravity, 5(1), [14]. https://doi.org/10.1038/s41526-019-0075-2

Supplying a pharmacy for NASA exploration spaceflight : challenges and current understanding. / Blue, Rebecca; Bayuse, Tina M.; Daniels, Vernie R.; Wotring, Virginia E.; Suresh, Rahul; Mulcahy, Robert A.; Antonsen, Erik L.

In: npj Microgravity, Vol. 5, No. 1, 14, 01.12.2019.

Research output: Contribution to journalReview article

Blue, R, Bayuse, TM, Daniels, VR, Wotring, VE, Suresh, R, Mulcahy, RA & Antonsen, EL 2019, 'Supplying a pharmacy for NASA exploration spaceflight: challenges and current understanding', npj Microgravity, vol. 5, no. 1, 14. https://doi.org/10.1038/s41526-019-0075-2
Blue, Rebecca ; Bayuse, Tina M. ; Daniels, Vernie R. ; Wotring, Virginia E. ; Suresh, Rahul ; Mulcahy, Robert A. ; Antonsen, Erik L. / Supplying a pharmacy for NASA exploration spaceflight : challenges and current understanding. In: npj Microgravity. 2019 ; Vol. 5, No. 1.
@article{d6ebaebc1ad0462d8e5416af74727943,
title = "Supplying a pharmacy for NASA exploration spaceflight: challenges and current understanding",
abstract = "In order to maintain crew health and performance during long-duration spaceflight outside of low-Earth orbit, NASA and its international partners must be capable of providing a safe and effective pharmacy. Given few directed studies of pharmaceuticals in the space environment, it is difficult to characterize pharmaceutical effectiveness or stability during spaceflight; this in turn makes it challenging to select an appropriate formulary for exploration. Here, we present the current state of literature regarding pharmaceutical stability, metabolism, and effectiveness during spaceflight. In particular, we have attempted to highlight the gaps in current knowledge and the difficulties in translating terrestrial-based drug studies to a meaningful interpretation of drug stability, safety, and effectiveness in space. We hope to identify high-yield opportunities for future research that might better define and mitigate pharmaceutical risk for exploration missions.",
author = "Rebecca Blue and Bayuse, {Tina M.} and Daniels, {Vernie R.} and Wotring, {Virginia E.} and Rahul Suresh and Mulcahy, {Robert A.} and Antonsen, {Erik L.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41526-019-0075-2",
language = "English (US)",
volume = "5",
journal = "npj Microgravity",
issn = "2373-8065",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Supplying a pharmacy for NASA exploration spaceflight

T2 - challenges and current understanding

AU - Blue, Rebecca

AU - Bayuse, Tina M.

AU - Daniels, Vernie R.

AU - Wotring, Virginia E.

AU - Suresh, Rahul

AU - Mulcahy, Robert A.

AU - Antonsen, Erik L.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - In order to maintain crew health and performance during long-duration spaceflight outside of low-Earth orbit, NASA and its international partners must be capable of providing a safe and effective pharmacy. Given few directed studies of pharmaceuticals in the space environment, it is difficult to characterize pharmaceutical effectiveness or stability during spaceflight; this in turn makes it challenging to select an appropriate formulary for exploration. Here, we present the current state of literature regarding pharmaceutical stability, metabolism, and effectiveness during spaceflight. In particular, we have attempted to highlight the gaps in current knowledge and the difficulties in translating terrestrial-based drug studies to a meaningful interpretation of drug stability, safety, and effectiveness in space. We hope to identify high-yield opportunities for future research that might better define and mitigate pharmaceutical risk for exploration missions.

AB - In order to maintain crew health and performance during long-duration spaceflight outside of low-Earth orbit, NASA and its international partners must be capable of providing a safe and effective pharmacy. Given few directed studies of pharmaceuticals in the space environment, it is difficult to characterize pharmaceutical effectiveness or stability during spaceflight; this in turn makes it challenging to select an appropriate formulary for exploration. Here, we present the current state of literature regarding pharmaceutical stability, metabolism, and effectiveness during spaceflight. In particular, we have attempted to highlight the gaps in current knowledge and the difficulties in translating terrestrial-based drug studies to a meaningful interpretation of drug stability, safety, and effectiveness in space. We hope to identify high-yield opportunities for future research that might better define and mitigate pharmaceutical risk for exploration missions.

UR - http://www.scopus.com/inward/record.url?scp=85067309656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067309656&partnerID=8YFLogxK

U2 - 10.1038/s41526-019-0075-2

DO - 10.1038/s41526-019-0075-2

M3 - Review article

AN - SCOPUS:85067309656

VL - 5

JO - npj Microgravity

JF - npj Microgravity

SN - 2373-8065

IS - 1

M1 - 14

ER -